Purpose: To report the effect of a single intravitreal bevacizumab injection on serous retinal detachment (SRD) in Sturge-Weber syndrome (SWS). Design: Interventional case report. Methods: A 15-year-old boy with history of SWS was referred with a complaint of sudden visual loss 2 days before, having choroidal hemangioma accompanied with SRD. Visual acuity was 20/160. Results: He was treated with 1.25 mg of bevacizumab injected intravitreally. One week later, the retina was completely attached and visual acuity was 20/20. After 20 months, without repeating the injection, the retina remained attached and vision was stable. Conclusions: An early single dose of intravitreal bevacizumab is effective in the treatment of serous retinal detachment in SWS with good long-term results.

Artificial intelligence (AI)-driven analysis of retinal images holds promise for noninvasive, early detection of neurodegenerative disorders. We conducted a prospectively registered systematic review and meta‑analysis to quantify diagnostic accuracy of AI‑assisted retinal imaging across Alzheimer's disease (AD), Parkinson's disease (PD), and related conditions. We searched six databases for studies (2010-2024) employing AI/ML models for binary classification of neurodegenerative disease versus healthy controls. Risk of bias was assessed using QUADAS-2. We extracted pooled area under the receiver operating characteristic curve (AUC) with 95 % confidence intervals (CIs), heterogeneity statistics, and participant numbers. Certainty of evidence was graded using GRADE criteria. Our analysis included ten studies (seven on AD, four on PD; 496 patients, 441 patients, and 36,990 healthy controls). The overall pooled AUC was 0.73 (95 % CI, 0.69-0.77; I²=78 %). Subgroup analyses showed an AUC of 0.72 for AD and 0.70 for PD. QUADAS-2 assessments indicated low-to-moderate risk of bias, with patient selection variability being a key concern. GRADE evaluations showed moderate to high certainty in the evidence. AI‑assisted retinal imaging demonstrates consistent, moderate accuracy for early detection of AD and PD. Future research should standardize imaging protocols and patient selection criteria, and pursue large-scale, prospective validation.